Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025

1 hour ago 1

Soumya Eswaran

Tue, February 3, 2026 astatine 7:30 AM CST 3 min read

Baron Funds, an concern absorption company, released its “Baron Discovery Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Fund focuses connected long-term, competitively positioned companies that are well-managed and person important imaginable successful untapped markets. The missive besides addressed the advancements successful AI and however humans specify themselves successful the changing landscape. In Q4, the money generated a instrumentality of 0.19% (Institutional Shares), underperforming the Russell 2000 Growth Index by 1.03 percent points. Over the full year, the money posted a instrumentality of 10.96%, portion the Index returned 13.01%. The outperformance of low-quality and short-term terms momentum-oriented stocks affected the Fund’s absorption connected semipermanent valuation metrics. The apical 10 holdings comprised 26.7% of the Fund’s nett assets, with currency making up 3.3%. The Fund maintains beardown optimism and expects a high-growth, low-inflation situation successful 2026. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Baron Discovery Fund highlighted stocks similar Exact Sciences Corporation (NASDAQ:EXAS). Exact Sciences Corporation (NASDAQ:EXAS) provides crab screening and diagnostic trial products and is simply a important contributor to the fund’s show successful the quarter. On February 2, 2026, Exact Sciences Corporation (NASDAQ:EXAS) banal closed astatine $102.50 per share. One-month instrumentality of Exact Sciences Corporation (NASDAQ:EXAS) was 0.84%, and its shares gained 87.21% of their worth implicit the past 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a marketplace capitalization of $19.47 billion.

Baron Discovery Fund stated the pursuing regarding Exact Sciences Corporation (NASDAQ:EXAS) successful its 4th fourth 2025 capitalist letter:

"Shares of Exact Sciences Corporation (NASDAQ:EXAS) contributed to performance. Exact is simply a molecular diagnostics institution focused connected the aboriginal detection of colorectal cancer. It is champion known for its non invasive colorectal crab screening stool trial called Cologuard. The large representation is that fractional of the 106 cardinal adults successful the U.S. recommended for colorectal crab screening are not up to date, and we deliberation the Cologuard trial presents the champion operation of non-invasiveness and close sensitivity/specificity arsenic compared to much invasive colonoscopies and little close humor tests. Exact shares outperformed successful 2025 arsenic the restructuring of the commercialized squad drove Cologuard measurement maturation reacceleration, and shares further outperformed arsenic Abbott Laboratories announced an statement to get Exact Sciences for $23 cardinal successful November. The woody represents a >50% premium implicit the anterior closing price."